Media ReleasesImmutep

View All Immutep News

Immutep - Positive initial data in phase 2 Soft Tissue Sarcoma trial

  • Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial
  • Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapies
  • Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need
  • Additional data from EFTISARC-NEO planned for a medical conference in H2 CY2024

SYDNEY, AUSTRALIA – 2 May 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces initial encouraging data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy, a standard-of-care treatment, plus KEYTRUDA® (pembrolizumab) for patients with soft tissue sarcoma (STS).

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?